“This agreement demonstrates the power of genetics in the drug discovery and development process,” said Greg Yap, vice president of DNA Products at Affymetrix. “We anticipate that a better understanding of human genetic variations will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster.”
The Affymetrix GeneChip 500K technology enables researchers to examine the entire genome in great detail, making it the first practical and affordable solution for association studies.
With the array set, scientists can perform an entire association study, from conducting an initial high-resolution scan of the entire genome to identifying the specific genetic variations of interest.